Market Research Report
Behavioral Disorders Drug Development Pipeline Review, 2017
|Published by||GlobalData||Product code||564937|
|Published||Content info||113 Pages
Delivery time: 1-2 business days
|Behavioral Disorders Drug Development Pipeline Review, 2017|
|Published: September 14, 2017||Content info: 113 Pages||
Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child's sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. There are a total of 41 products in development for this indication, by 34 companies and 4 academic institutions. Key companies operating in this pipeline space include Addex Therapeutics, Confluence Pharmaceuticals and Immuron.
Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead to do repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. There are a total of 8 products in development for this indication by 7 companies. Key companies operating in this pipeline space include Addex Therapeutics, Abbvie, Omeros and Phytecs.
Finally, attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. There are a total of 58 products in development for this indication, by 41 companies and 5 academic institutions. Key companies operating in this pipeline space include NLS Pharma, Aevi Genomic Medicine, Shire and Highland Therapeutics.
Across all three of these indications, transporters and receptors of neurotransmitters such as dopamine, glutamine and serotonin, plus G protein-coupled receptors and ion channels, are the most common targets, closely reflecting the current treatment landscape of these diseases.
The report, "Behavioral Disorders Drug Development Pipeline Review, 2017" provides an overview of the behavioral disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for autism, obsessive-compulsive disorder and attention deficit hyperactivity disorder and features dormant and discontinued projects.